Show simple item record

dc.contributor.authorCarew, Jennifer S
dc.contributor.authorEspitia, Claudia M
dc.contributor.authorZhao, Weiguo
dc.contributor.authorVisconte, Valeria
dc.contributor.authorAnwer, Faiz
dc.contributor.authorKelly, Kevin R
dc.contributor.authorNawrocki, Steffan T
dc.date.accessioned2019-08-20T22:08:50Z
dc.date.available2019-08-20T22:08:50Z
dc.date.issued2019-04-23
dc.identifier.citationCarew, J. S., Espitia, C. M., Zhao, W., Visconte, V., Anwer, F., Kelly, K. R., & Nawrocki, S. T. (2019). Rational cotargeting of HDAC6 and BET proteins yields synergistic antimyeloma activity. Blood advances, 3(8), 1318-1329.en_US
dc.identifier.issn2473-9529
dc.identifier.pmid31015208
dc.identifier.doi10.1182/bloodadvances.2018026484
dc.identifier.urihttp://hdl.handle.net/10150/633900
dc.description.abstractInhibition of bromodomain and extra terminal (BET) protein family members, including BRD4, decreases the expression of c-MYC and other key oncogenic factors and also significantly induces histone deacetylase 6 (HDAC6) expression. On the basis of the role of HDAC6 in malignant pathogenesis, we hypothesized that rational cotargeting of HDAC6 and BET family proteins may represent a novel approach that yields synergistic antimyeloma activity. We used genetic and pharmacologic approaches to selectively impair HDAC6 and BET function and evaluated the consequential impact on myeloma pathogenesis. These studies identified HDAC6 upregulation as an efficacy reducing mechanism for BET inhibitors because antagonizing HDAC6 activity synergistically enhanced the activity of JQ1 in a panel of multiple myeloma (MM) cell lines and primary CD138+ cells obtained from patients with MM. The synergy of this therapeutic combination was linked to significant reductions in c-MYC expression and increases in apoptosis induction. Administration of the clinical HDAC6 inhibitor ricolinostat was very well tolerated and significantly augmented the in vivo antimyeloma activity of JQ1. Ex vivo pharmacodynamic analyses demonstrated that the combination of JQ1 and ricolinostat led to significantly lower MM cell proliferation and increased apoptosis and diminished expression of c-MYC and BCL-2. These data demonstrate that cotargeting of HDAC6 and BET family members is a novel and clinically actionable approach to augment the efficacy of both classes of agents that warrants further investigation.en_US
dc.description.sponsorshipNational Institutes of Health, National Cancer Institute [R01CA190789, R01CA172443]; University of Arizona Cancer Center Support Grant [P30CA023074]en_US
dc.language.isoenen_US
dc.publisherAMER SOC HEMATOLOGYen_US
dc.rights© 2019 by The American Society of Hematologyen_US
dc.titleRational cotargeting of HDAC6 and BET proteins yields synergistic antimyeloma activityen_US
dc.typeArticleen_US
dc.contributor.departmentUniv Arizona, Div Hematol & Oncolen_US
dc.identifier.journalBLOOD ADVANCESen_US
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.en_US
dc.eprint.versionFinal published versionen_US
dc.source.journaltitleBlood advances
refterms.dateFOA2019-08-20T22:08:51Z


Files in this item

Thumbnail
Name:
1318.full.pdf
Size:
2.124Mb
Format:
PDF
Description:
Final Published Version

This item appears in the following Collection(s)

Show simple item record